Purpose: We performed a phase I/II study evaluating the combination of paclitaxel and carboplatin as first-line chemotherapy in patients with advanced ovarian cancer. The aim of this study was to define a feasible and safe combination regimen that could be recommended for future phase III studies.
Introduction
Over the last 15 years, standard first-line therapy of advanced ovarian cancer has been based on radical surgery followed by a platinum-containing combination chemotherapy. The introduction of cisplatin has increased the efficacy of chemotherapy compared to nonplatinum based regimens [1, 2] . Further improvement of first-line chemotherapy of ovarian cancer was achieved when carboplatin was introduced and showed comparable efficacy but less toxicity than cisplatin, especially nephrotoxicity, neurotoxicity, and emesis [3] [4] [5] . Paclitaxel was introduced into chemotherapy of ovarian cancer in the eighties. Phase II studies in pretreated ovarian cancer demonstrated remarkable efficacy [6] [7] [8] . Consequently, the Gynecologic Oncology Group (GOG) initiated a phase III study in first-line chemotherapy comparing the standard regimen cisplatin plus cyclophosphamide to cisplatin plus paclitaxel given as 24-hour infusion. The final results of this study have been published recently demonstrating a survival advantage for the combination of cisplatin and paclitaxel [9] . As expected, the combination of two drugs with a potential of inducing peripheral neurotoxicity produced more neurotoxicity than the (old) standard regimen. Furthermore, the new combination induced significantly more myelosuppression, which might be related to the prolonged paclitaxel infusion. In fact, a European-Canadian study in pretreated ovarian cancer patients comparing three-hour versus 24-hour paclitaxel infusion has demonstrated significantly less myelotoxicity without reduced efficacy for the three-hour infusion schedule [10] . We identified two possible options for reducing the major toxicities observed with cisplatinum-paclitaxel: a reduction of the paclitaxel infusion time should ameliorate myelosuppression and the substitution of cisplatin by carboplatin should minimize neurotoxicity.
So far, five phase I/II studies evaluating the combination of carboplatin and paclitaxel as first-line chemotherapy of advanced ovarian cancer have been initiated: the GOG study [11] , the EORTC study [12] , an UK study [13] , an Italian study [14] , and the present study by the AGO Study Group (Arbeitsgemeinschaft Gynakologische Onkologie, Germany). Except the US study, that started with a 24-hour infusion schedule for paclitaxel, all studies were initiated with a three-hour infusion schedule for paclitaxel. The US study later switched to the three-hour schedule, too.
carboplatin dose was fixed to an AUC 5 and paclitaxel was escalated in 25 mg/m 2 steps with a starting dose of 135 mg/m 2 . After the MTD of paclitaxel was reached, the two arms were compared with respect to toxicity. The more favourable arm (arm 1) was continued and carboplatin was escalated until MTD was reached.
Bidimensionally measurable tumors were not mandatory for inclusion, but patients who presented with measurable tumors were evaluated for response. Gynecological clinical examinations were performed before each course. Imaging techniques appropriate for tumor measurement were performed every other course. Responses that were primarily detected by clinical examination or ultrasound had to be verified by CT scan. Response was defined according to the UICC criteria [18] ,
Patients and methods Results
This study was conducted according to the GCP guidelines. Approval from ethics committees were gained at every institution and each patient gave written informed consent. Inclusion criteria were histologically confirmed epithelial ovanan cancer, age > 18 and ^ 75 years, Eastern Cooperative Oncology Group performance status of 2 or better, and adequate bone-marrow function (absolute neutrophil count >2 x 1O 9 /1 and platelet count > 100 x 1O 9 /1), adequate renal and hepatic function (creatinine and bilirubine $1.25 x upper limit of normal). Patients were ineligible, if they had prior malignancies excluding non-melanomatous skin cancer, prior chemo-or radiotherapy, a history of atnal or ventricular arrhythmias, congestive heart failure or a history of myocardial infarction, pre-existing motor or sensory neurotoxicity of WHO grade 2 or greater, active infection, bowel obstruction, and mental disorders.
Carboplatin dose was calculated as AUC according to the Calvert formula [15] , The glomerular filtration rate was estimated according to the Jeliffe formula [16] Carboplatin was diluted in 500 ml glucose 5% and infused over 30-60 minutes. Paclitaxel (Taxol*, Bnstol-MyersSquibb) was diluted in 500 ml normal saline and infused over threehours. Premedication consisted of single-dose 20 mg dexamethasone, 2 mg clemastine, and 50 mg ranitidine given intravenously 30' prior to the paclitaxel administration. Ondansetron 8 mg was given as short infusion before carboplatin. The treatment was repeated every 21 days for a maximum of six courses. Each patient was observed for at least 24 hours following paclitaxel infusion. Blood counts were taken during each course, once in the first week and twice in the second and third week. Toxicity was graded according to the WHO classification [18] . G-CSF was allowed as secondary prophylaxis if a patient had experienced WHO grade IV neutropenia lasting for more than three days in the previous course.
The maximum tolerated dose (MTD) was defined at one level below the dose level in which at least two of six patients developed dose-limiting toxicity (DLT). DLT was defined as (1) ANC < 0.5 x 10 9 /l lasting for more than seven days, (2) ANC <0.1 x 1O 9 /1 lasting for more than three days, (3) febrile neutropenia, (4) WHO grade IV thrombocytopenia, (5) clinically relevant neurotoxicity WHO grade 3, (6) other toxicities WHO grade 4. Re-treatment was delayed until thrombocyte counts had reached 100 x 10 9 /l and ANC was > 1.5 x IO 9 /1. Patients went offstudy if the treatment interval exceeded 42 days. DLT was evaluated over the first four consecutive courses per patient. Patients were enrolled in the next higher dose level only in absence of DLT within the first four courses in three patients in the preceeding dose level. After defining the MTD level, further six patients had to be treated for confirmation in this dose level.
This study was initiated as a two arm study in order to evaluate whether clinically relevant pharmacokinetic interactions were occurring between carboplatin and paclitaxel, as it has been shown for cisplatin and paclitaxel combinations [17] . In arm 1 carboplatin infusion was started directly following paclitaxel infusion on day 1. In arm 2 carboplatin was administered 24 hours following paclitaxel infusion. Patient recruitment was non-randomized and recruitment for each study arm switched after every three patients enrolled. As first step Sixty-one patients were enrolled. Fifty-nine patients having received 286 courses were found eligible and evaluable for toxicity. Two patients were excluded because Cr-EDTA clearance had been used to calculate the carboplatin dose. These patients received a higher dose than patients in whom AUC calculation was based on GFR estimation. Thirty-four patients presented with bidimensionally measurable disease of whom 33 were evaluable for response. One patient received only one course of chemotherapy and was therefore not included into the efficacy analysis.
The study population included in either the singleday schedule (arm 1) or the two-day-schedule (arm 2) did not show any significant differences with respect to age, performance status, or FIGO stage ( Table 1) . The majority of patients presented with FIGO stage III ovarian cancer and about half of the patients in each arm had measurable tumors. Thirty-eight patients receiving 193 courses were enrolled into arm 1 and 21 patients with 93 courses were enrolled into arm 2. The imbalance of recruitment in favour of arm 1 is explained by the study design. The two-day-schedule (arm 2) was closed following interim analysis after completion of level IV (paclitaxel 210 mg/m 2 plus carboplatin AUC 5) and further patients were enrolled into arm 1 only. 
Hematological toxicity
At least half of all patients in each dose level and in both study arms experienced neutropenia WHO grade III or grade IV (Tables 2a and 2b ). Nevertheless, the duration of the nadir was short and neutropenic fever or septic complications were observed in only one patient. The latter patient represented the only case of treatment related death. She died during a period of neutropenic sepsis accompanied by thrombopenic hemorrhage following the first course of carboplatin AUC 7.5 and paclitaxel 185 mg/m 2 given as one-day regimen. Thrombocytopenia was rare and WHO grade III/IV toxicity following carboplatin AUC 5 was observed exclusively in the two-day schedule in 4/21 patients. The escalation of carboplatin to AUC 6 and AUC 7.5 induced thrombocytopenia WHO grade III/IV in the one-day schedule in 5 of 17 patients. Hematologic DLT was observed in 10 patients: six patients (three in each study arm) developed neutropenia fulfilling the criteria defined as DLT, three patients developed grade III/IV thrombocytopenia, and one patient developed fatal neutropenia and thrombocytopenia. Overall, severe neutropenia WHO grade III or higher was more frequently observed in the two-dayschedule. G-CSF was administered in 30% of the courses in the two-day schedule and in 7% of the courses in the one-day schedule, respectively. G-CSF use was reported not earlier than in course 3 in the majority of patients and was associated with higher paclitaxel doses. In both arms, G-CSF treatment did not allow further dose escalation, although the duration of the nadir was reduced in some patients.
Non-hematological toxicity
Peripheral neurotoxicity was the major non-hematological toxicity. The clinical course of WHO grade II neurotoxicity included paresthesia, numbness, and burning sensations, which were typically limited to the hands and feet. Most patients reported their symptoms commencing after course 2 or 3. Usually, the duration of symptoms not their severity increased over subsequent courses. Most of the affected patients reported neurotoxicity lasting for the whole 21 days interval after course 5. All patients reported an improvement after chemotherapy had been completed and restitution was gained within six months in the majority of patients. Three patients developed grade III neurotoxicity and one patient suffered from grade IV neurotoxicity. The latter patient was unable to walk due to weakness in the legs. Symptoms lasted for one day and recovery commenced spontaneously. The incidence of neurotoxicity did not differ significantly between both study arms. Paclitaxel dose escalation did not show a linear correlation with the frequency or severity of neurotoxicity (Table 3) . Further dose escalations of carboplatin above AUC 5 led to an increase of neurotoxicity, but numbers are too small to make definitive conclusions. Each case of neurotoxicity was discussed within the study group and only two patients were judged as having a DLT. The remaining two patients who presented with grade III neurotoxicity reported only transient symptoms of very short duration that resolved spontaneously and did not lead to a modification of chemotherapy.
Among other non-hematologic toxicities alopecia was the most frequently observed. Almost all patients lost their hair after two courses of paclitaxel. Some patients reported re-growing hair after course 5 and alopecia recovered in all patients after completion of chemotherapy. Myalgia and arthralgia WHO grade II or higher were observed in 17 of 59 patients (29%). These symptoms commenced typically two days following paclitaxel and lasted for 3-5 days. Some patients used paracetamol or diclofenac for pain relief, others reported cooling to be helpfull, whilst some patients reported hot bathes or walking to be beneficial.
Deep pelvic vein thrombosis was observed in two patients by CT scanning. These patients were enrolled into dose level III in the one-day arm. The clinical course and previous CT scans were re-analysed and the occurrence of the thrombosis was judged to be associated with surgery and/or the underlying cancer. Both patients were not regarded as having a DLT, but additional six patients were enrolled into this dose level. None of these six patients showed further DLTs.
Dose intensity
The majority of patients received at least four chemotherapy courses and only 14 patients (24%) received less than five courses. Withdrawal from the study was due to toxicity in 12 patients and due to progressive disease in two patients. Most of the 12 patients who went off study due to DLT received further treatment, in most cases carboplatin single agent therapy. Thirty-one of 38 patients (82%) in arm 1 and 16 of 21 patients (76%) in arm 2 received at least five courses. Although commonly observed, myelosuppression did not significantly alter the dose intensity measured by the period between subsequent chemotherapy courses ( Table 4 ). The extension of the interval between subsequent courses for more than seven days was observed in 34 of 286 courses (12%). The mean carboplatin dose was about 420 mg/ m 2 when AUCs were transformed into mg/m 2 . G-CSF treatment reduced treatment delay in the two-day arm in some patients. In the one-day arm G-CSF was given in only 7% of courses, therefore G-CSF might have contributed to a very small extent to dose intensity variations in this study arm.
Tumor response
Thirty-three of 59 patients (56%) presented with bidimensionally measurable disease and received more than one course of chemotherapy. Response assessment in patients who went off study was limited to the reponse observed while the patient was on study. Overall objective responses were observed in 23 of 33 patients (70%), including eight patients showing a complete response (24%). Responses were observed within each study arm and within each dose level except the lowest dose level in arm 1. Progressive disease during chemotherapeutic treatment was observed in two patients only.
Maximal tolerated dose (MTD)
Patients were enrolled into both study arms until dose level IV was completed. Dose limiting toxicity (DLT) was observed in both study arms in at least two patients when paclitaxel was escalated to 210 mg/m 2 (Table 5) . Therefore, MTD for paclitaxel was reached at 185 mg/ m 2 when combined with carboplatin at a fixed dose of AUC 5. An interim analysis comparing both study arms level I-IV revealed advantages for the one-day schedule so that arm 1 was continued with an escalation of carboplatin dose. Overall, the two-day schedule induced more hematologic toxicity, and consequently G-CSF was administered more frequently in this study arm (30% of courses compared to 7% of courses in arm 1). Furthermore, the two-day schedule was more inconvenient and needed a longer period of hospitalization for drug administration.
As second step paclitaxel was administered at a fixed dose of 185 mg/m 2 and carboplatin dose was escalated to AUC 6 without DLT being observed in three patients. Further escalation of carboplatin to AUC 7.5 resulted in hematologic DLT in 4 of 6 patients including one fatal event. Therefore, MTD was defined at a carboplatin dose of AUC 6. Further eight patients were included into the MTD level (paclitaxel 185 mg/m 2 plus carboplatin AUC 6). Overall, only 2 of 11 patients in this dose level experienced toxicity defined as DLT. The study was Table 5 . Recruitment and incidence of dose limiting toxicity (DLT) for each study arm and each dose level. (2) ;tudy arm closed a These cases were not regarded as DLT (see text for explanation). b One patient experienced both neutropenia and thrombocytopenia. c Two patients (one patient experienced both thrombocytopenia and neurotoxicity).
stopped at this point and the above mentioned regimen was recommended for further phase III studies.
Discussion
Following the publication of the GOG 111 trial [9] , the combination of cisplatin and paclitaxel has been advocated as new standard treatment of advanced ovarian cancer [19] . The randomized comparison of paclitaxel plus cisplatin with cisplatin plus cyclophosphamide has shown superior results with respect to median progression-free interval, median survival, and objective response rates for the new combination. The improvement regarding efficacy were traded for a significantly higher rate of myelosuppression and a non-significant higher rate of neurotoxicity. However, the overall benefit seems to justify further evaluation of the combination of taxanes and platinum co-ordination complexes as firstline chemotherapy in epithelial ovarian cancer. The EORTC has recently closed a randomized confirmatory study comparing cisplatin plus cyclophosphamide with paclitaxel three-hour infusion plus cisplatin in about 600 patients (EORTC protocol # 55931). Meanwhile, further trials were initiated trying to improve the therapeutic index of the combination of paclitaxel and platinum.
Infusion time has been correlated with the incidence of severe myelosuppression. Paclitaxel three-hour infusions induced significantly less myelosuppression than 24 hour infusions without compromising efficacy [10] . This has been demonstrated only for paclitaxel singleagent therapy in pre-treated patients with ovarian cancer and evidence in first-line chemotherapy is lacking. A comparison of three-hour infusion with 24 hour infusion has been performed by the GOG and will be published in the near future. Nevertheless, most currently activated studies including the EORTC trial used the threehour infusion schedule, which is more convenient, induces less costs for hospitalization, and probably will demonstrate a superior toxicity profile at least as far as myelosuppresion is concerned.
Additional efforts are directed to reduce the second most relevant toxicity following cisplatin combined with paclitaxel. In the GOG 111 study, the combination of two potentially neurotoxic drugs, i.e., cisplatin and paclitaxel, has resulted in a 13% incidence of neurotoxicity of more than grade I [9] . In contrast, the old standard combination containing only one potentially neurotoxic drug induced less neurotoxicity. Carboplatin, which is regarded as equieffective against ovarian cancer [20] , possesses less neurotoxic potential compared to its parent compound cisplatin [21] . Therefore, five groups have initiated phase I/II studies to evaluate the combination of paclitaxel and carboplatin [11] [12] [13] [14] . The European groups used a three-hour infusion schedule for paclitaxel and the GOG evaluated the three-hour and the 24-hour infusion schedule. The currently available results of these trials regarding MTD and DLT are summarized in Table 6 . Comparison of these results is hampered by the heterogenous study designs. Our results are similar to the results provided by the GOG trial [11] . The carboplatin dose of AUC 7.5 as reported by the GOG is higher than the MTD for carboplatin in our study. The difference with respect to dose intensity might be smaller, because the mean intervals between subsequent courses are shorter in our study. Our experience regarding secondary G-CSF prophylaxis is similar to the GOG experience. G-CSF might help to reduce treatment delay in subsequent courses, but does not allow dose escalation. Therefore, in case of prolonged hematological recovery we rather recommend treatment delay for up to seven days than generally G-CSF administration.
The spectrum of dose limiting toxicities is comparable in all five studies and consists of myelosuppression and neurotoxicity (Table 6 ). Results of these early clinical trials substituting cisplatin by carboplatin are somewhat disappointing regarding the incidence of neurotoxicity. Today, it is too early to draw final conclusions, but the rates of neurotoxicity observed in these phase II II trials do not show a very promising reduction of this toxicity when compared with those of the GOG 111 trial. The relatively high incidence of neurotoxicity may be due to the higher paclitaxel doses that are used in these phase I/II trials compared to only 135 mg/m 2 in the GOG 111 trial. Furthermore, considering an equivalence factor of 1: 4 for cisplatin : carboplatin, the carboplatin dose found MTD in our trial (on average about 420 mg/m 2 every three weeks) is higher than the platinum dose of 75 mg/m 2 cisplatin used in the GOG 111 trial. Carboplatin is less neurotoxic compared to cisplatin [21] , but neurotoxicity has been reported following carboplatin therapy, too. Therefore, it seems possible, that carboplatin and paclitaxel act synergistically with respect to neurotoxicity. This hypothesis is supported by our observation that carboplatin dose escalation leads to an increase of neurotoxicity. Nevertheless, neurotoxicity was clinically manageable and resolved spontaneously in all but one patient.
Our goal was to develop a clinically feasable and safe regimen which could be recommended for phase III studies. The regimen that met our requirements for recommendation for phase III trials was paclitaxel 185 mg/m 2 given as three-hour infusion followed by carboplatin AUC 6. The overall response rate of 70% justifies further evaluation of this combination regimen. In October 1995 we initiated a randomized phase III trial comparing paclitaxel in combination with either carboplatin or cisplatin. Today, 560 of 660 planned patients have been enrolled.
